Amgen, Pfizer sales and marketing update

Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) said in an early benefit assessment that an added benefit for Ibrance palbociclib “is not proven” vs. comparator therapy to treat hormone receptor-positive breast cancer. The agency said the dossier did not include suitable data on several groups of patients, and where data were available, severe side effects were more frequent under treatment with palbociclib in combination than under letrozole alone, which the agency said “resulted in an indication of lesser benefit.”...